ClinicalTrials.gov registry snapshot / 2026-07-24

Peptide trials,
without the maze.

Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.

268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program

Study status is not drug rank.

Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.

Official registry finder

Filter the exact records.

Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.

Reset
13matching registry records
Matching recruiting site observations68
Program and recordStatusPhase and enrollmentLocationsPrimary completionRegistry updateSource
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightNCT07339423 / AMAZE 1 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 31,150 estimated6 matching recruitingBrussels, 1070, Belgium / Edegem, 2650, Belgium / Ghent, 9000, Belgium / 3 more areasJun 26, 2029estimatedJul 9, 2026ClinicalTrials.govOpen NCT07339423
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight LossNCT07503210 / AMAZE 12 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 3600 estimated3 matching recruitingDiepenbeek, 3590, Belgium / Kortrijk, 8500, Belgium / Liège, 4000, BelgiumJun 6, 2028estimatedJul 9, 2026ClinicalTrials.govOpen NCT07503210
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 3460 estimated0 matching recruitingNo city or postal detail is present for the matching registry rows.Mar 20, 2030estimatedJul 17, 2026ClinicalTrials.govOpen NCT07253285
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 32,500 estimated0 matching recruitingNo city or postal detail is present for the matching registry rows.Feb 23, 2028estimatedJul 8, 2026ClinicalTrials.govOpen NCT07564414
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 / ENLIGHTEN-1 / Eli Lilly and CompanyRecruitingVerified 2026-07Phase 31,980 estimated4 matching recruitingDiepenbeek, 3590, Belgium / Hasselt, 3500, Belgium / Kluisbergen, 9690, Belgium / 1 more areaMar 2028estimatedJul 17, 2026ClinicalTrials.govOpen NCT07321886
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931 / ENLIGHTEN-4 / Eli Lilly and CompanyRecruitingVerified 2026-07Phase 3900 estimated5 matching recruitingGenk, 3600, Belgium / Ghent, 9000, Belgium / Kluisbergen, 9690, Belgium / 2 more areasMar 2028estimatedJul 17, 2026ClinicalTrials.govOpen NCT07353931
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 / ENLIGHTEN-6 / Eli Lilly and CompanyRecruitingVerified 2026-07Phase 3900 estimated7 matching recruitingBonheiden, 2820, Belgium / Genk, 3600, Belgium / Ieper, 8900, Belgium / 3 more areasJun 2028estimatedJul 17, 2026ClinicalTrials.govOpen NCT07392190
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 / Enith1 / Hoffmann-La RocheRecruitingVerified 2026-07Phase 32,000 estimated5 matching recruitingAalst, 9300, Belgium / Brussels, 1070, Belgium / Leuven, 3000, Belgium / 2 more areasJul 24, 2028estimatedJul 20, 2026ClinicalTrials.govOpen NCT07351045
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 / MARITIME-CV / AmgenRecruitingVerified 2026-07Phase 312,800 estimated12 matching recruitingAalst, 9300, Belgium / Bonheiden, 2820, Belgium / Bruges, 8000, Belgium / 9 more areasJun 30, 2028estimatedJul 24, 2026ClinicalTrials.govOpen NCT07037433
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 / MARITIME-HF / AmgenRecruitingVerified 2026-06Phase 35,056 estimated14 matching recruitingAalst, 9300, Belgium / Dendermonde, 9200, Belgium / Genk, 3600, Belgium / 9 more areasJun 30, 2028estimatedJul 2, 2026ClinicalTrials.govOpen NCT07037459
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 / Eli Lilly and CompanyRecruitingVerified 2026-07Phase 34,500 estimated3 matching recruitingGhent, 9000, Belgium / Ostend, 8400, Belgium / Roeselare, 8800, BelgiumAug 2030estimatedJul 17, 2026ClinicalTrials.govOpen NCT07165028
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444 / Boehringer IngelheimRecruitingVerified 2026-07Phase 31,800 estimated5 matching recruitingBrussels, 1070, Belgium / Edegem, 2650, Belgium / Genk, 3600, Belgium / 2 more areasDec 27, 2031estimatedJul 9, 2026ClinicalTrials.govOpen NCT06632444
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisNCT06632457 / Boehringer IngelheimRecruitingVerified 2026-07Phase 31,590 estimated4 matching recruitingBrussels, 1070, Belgium / Edegem, 2650, Belgium / Genk, 3600, Belgium / 1 more areaJun 5, 2029estimatedJul 9, 2026ClinicalTrials.govOpen NCT06632457
Clinical trial finder FAQ

Status, location, and enrollment are different fields.

These answers prevent the most common registry-search errors before a reader follows an official source.

01

Are any Retatrutide clinical trials recruiting?

Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.

02

How do I find a peptide clinical trial near me?

Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.

03

Does Recruiting mean I can join the trial?

No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.

04

Are the drugs in this clinical trial finder FDA approved?

A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.

05

Why do only some registry records show posted results?

11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.

06

How current is the peptide clinical trial data?

The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.

Evidence boundary

A registry finder, not an enrollment service.

A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.

Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.

Read the official API documentation ↗Understand evidence categories →